UCB selected Gwinnett County, Georgia, for a new U.S. biologics manufacturing facility expected to cost about $2 billion, expanding local production capacity for complex biologics. The planned campus is roughly 460,000 square feet and is intended to supply the U.S. market as part of UCB’s broader biologics network. UCB said the site will use a digital-first approach leveraging AI, robotics, and automation while emphasizing resource efficiency. The company also cited its intent to strengthen supply resilience and support its pipeline with additional manufacturing throughput for ongoing and future biologics programs. For the sector, the announcement underscores continued capital investment in domestic biologics capacity as manufacturers work to reduce scale-up and supply-risk constraints.